The estimated Net Worth of Anand Mehra is at least $204 Million dollars as of 1 June 2024. Anand Mehra owns over 4,660 units of Merus N.V stock worth over $2,180,342 and over the last 10 years he sold MRUS stock worth over $201,966,085. In addition, he makes $121,125 as Non-Executive Independent Chairman of the Board at Merus N.V.
Sign up
Anand Mehra MRUS stock SEC Form 4 insiders trading
Anand has made over 39 trades of the Merus N.V stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,660 units of MRUS stock worth $234,305 on 1 June 2024.
The largest trade he's ever made was selling 1,008,022 units of Merus N.V stock on 9 July 2014 worth over $24,212,688. On average, Anand trades about 99,403 units every 57 days since 2014. As of 1 June 2024 he still owns at least 43,364 units of Merus N.V stock.
You can see the complete history of Anand Mehra stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anand Mehra biography
Dr. Anand Mehra M.D. has been appointed as Non-Executive Independent Chairman of the Board of the Company. Dr. Mehra was nominated to serve on our board of directors by Sofinnova Venture Partners IX, L.P., one of our shareholders, and has been a non-executive member of our board of directors since August 2015. Dr. Mehra has been with Sofinnova Investments (f.k.a. Sofinnova Ventures) since 2007, most recently holding the position of a general partner where he focuses on working with entrepreneurs to build drug development companies. He has led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC. He currently serves as a member of the boards of directors of Spark Therapeutics, Inc. and Aclaris Therapeutics, Inc., as well as on the boards of several private companies. Dr. Mehra holds his M.D. from Columbia University’s College of Physicians and Surgeons.
What is the salary of Anand Mehra?
As the Non-Executive Independent Chairman of the Board of Merus N.V, the total compensation of Anand Mehra at Merus N.V is $121,125. There are 8 executives at Merus N.V getting paid more, with Hui Liu having the highest compensation of $1,382,530.
How old is Anand Mehra?
Anand Mehra is 44, he's been the Non-Executive Independent Chairman of the Board of Merus N.V since 2020. There are 14 older and 2 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.
What's Anand Mehra's mailing address?
Anand's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.
Insiders trading at Merus N.V
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... und Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
What does Merus N.V do?
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
What does Merus N.V's logo look like?
Complete history of Anand Mehra stock trades at Aclaris Therapeutics Inc, Aerie Pharmaceuticals Inc, Marinus Pharmaceuticals Inc und Merus N.V
Merus N.V executives and stock owners
Merus N.V executives and other stock owners filed with the SEC include:
-
Hui Liu,
Chief Business Officer and Head of Merus U.S. -
Dr. Sven Ante Lundberg M.D.,
CEO, Pres, Principal Financial Officer & Exec. Director -
Peter B. Silverman J.D.,
Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal -
Hui Liu,
Chief Bus. Officer, Exec. VP & Head of Merus U.S. -
Alexander Bakker,
Chief Development Officer -
Peter Silverman,
General Counsel, Chief Intellectual Property Officer and Head of US Legal -
John de Kruif,
Chief Technology Officer -
Sven Lundberg,
President, Chief Executive Officer, Principal Financial Officer, Executive Director -
Anand Mehra,
Non-Executive Independent Chairman of the Board -
Andrew Joe,
Chief Medical Officer -
Paolo Pucci,
Non-Executive Independent Director -
Victor Sandor,
Non-Executive Independent Director -
Jillian Connell,
Investor Relations & Corporate Communications -
Leonard Kanavy,
Non-Executive Independent Director -
Gregory Perry,
Independent Non-Executive Vice Chairman of the Board -
Mark Iwicki,
Non-Executive Independent Director -
Shannon Campbell,
Exec. VP & Chief Commercial Officer -
Dr. Cecile A.W. Geuijen Ph.D.,
Chief Scientific Officer -
Anne Noordzij,
Sec. -
Dr. Ellen Broug,
Exec. Director of IP & Sec. -
Dr. Andrew Joe M.D.,
Chief Medical Officer -
Alexander Berthold Hendrik Bakker Ph.D.,
Chief Devel. Officer & Sr. VP -
Cornelis Adriaan de Kruif Ph.D.,
CTO & Sr. VP -
Dr. Hennie Hoogenboom,
Co-Founder and Scientific Advisor -
Partners L P/Ilbiotechnolog...,
-
Lex Bakker,
SVP, Chief Development Officer -
Mark Throsby,
EVP & Chief Scientific Officer -
Partners L P/Ilbiotechnolog...,
-
Corp Incyte,
10% owner -
Cecile A W Geuijen,
SVP & Chief Scientific Officer -
Jason Haddock,
-
Maxine Gowen,
-
Len Kanavy,
-
Harry Shuman,
VP Controller, PAO -
Fabian Zohren,
Chief Medical Officer